Understanding multiple causes of racial disparities in breast cancer is essential

September 5, 2013

Racial disparities in the treatment and outcome of breast cancer patients arise from a combination of biological, social and financial causes. Understanding how these complex factors influence interactions between patients and the medical community is key to reducing the gaps in treatment and mortality between racial groups, according to researchers at the University of North Carolina.

Ollila appointed James H. and Jesse E. Millis Distinguished Professor

August 26, 2013

David Ollila, MD, professor of surgery, has been appointed to the James H. and Jesse E. Millis Distinguished Professorship. The $1.5 million professorship was established by their son, William (Bill) Millis in honor of his parents, Jim and Jesse Millis of High Point, N.C.

Amos quoted in ABC News feature

July 13, 2012

Keith Amos, MD, assistant professor of surgery at UNC-Chapel Hill, is quoted in an ABC News feature discussing a new study about partial breast removal surgery to treat cancer.

Exercise, even mild physical activity, may reduce breast cancer risk

June 25, 2012

A new analysis done by University of North Carolina at Chapel Hill researchers has found that physical activity – either mild or intense and before or after menopause – may reduce breast cancer risk, but substantial weight gain may negate these benefits.

Combination therapy for triple-negative breast cancer disappointing

June 12, 2012

CHAPEL HILL, N.C. – A recent clinical trial testing a combination therapy for basal-like (also known as triple-negative) breast cancer demonstrates that a combination of two drugs with promising preclinical results is not as effective as researchers had hoped.

Grant to fund use of kinase test in HER2-positive breast cancer

May 14, 2012

Chapel Hill, NC – Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer.